Uncategorized //

IntegraGen Announces Collaboration with Google Cloud to Offer Large Scale Genomic Analysis Tools for Clinicians and Medical Researchers

IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools.

(…)  » 

Uncategorized //

IntegraGen Reports Financial Results for 1st Half of 2018

IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018.

Sales revenue: 3.7 M€, +17% vs. H1 2017 Significant growth in genomics services Operating profit: -0.5 M€, + 57% vs. (…)  » 

News //

IntegraGen nominated for a 2018 PrixGalien MedStartup Award

IntegraGen has been nominated for a 2018 PrixGalien MedStartup Award, a joint initiative between The Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. IntegraGen was selected as a nominee by an (…)  » 

News //

IntegraGen’s licensing partner GoPath Labs announces new CPT Code for reimbursement of miR-31-3p test in the U.S.

GoPath Laboratories, IntegraGen’s North American licensing partner for the company’s miR-31-3p test, announced that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of miR-31now®, a proprietary miRNA-based molecular test which predicts the potential clinical benefits associated with (…)  » 

Uncategorized //

IntegraGen Announces Publication of miR-31-3p Data in Clinical Cancer Research

IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation of miR-31-3p Expression Level to Predict (…)  » 

Uncategorized //

The SeqOIA Cooperative Health Group selects IntegraGen as the operator of its sequencing platform as part of the France Genomic Medicine 2025 Plan

integragen

IntegraGen has announced that it has been selected by the Sequencing Omics Information Analysis (SeqOIA) Cooperative Health Group (GCS) for the operation of its high throughput sequencing platform. The SeqOIA GCS, which includes the Assistance Publique- Hôpitaux de Paris, the Institut Curie and the Gustave Roussy Cancer Center, (…)  »